Citations to the scientific publications of Edward Tobinick

The articles:

Tobinick, E.L. and H. Gross, Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation, 2008. 5(1): p. 2. [link to full-text PDF].

Edward Tobinick MD. Perispinal etanercept for treatment of Alzheimer's disease. Current Alzheimer Research 2007, 4(5):550-552. [link to abstract].

Tobinick, E., Paradigm Shift: Excess TNF-Alpha Emerges as a Key Therapeutic Target in Alzheimer's Disease. MedGenMed, 2007. 9(3): p. 17.

Edward Tobinick MD
Spinal Delivery of p38: TNF-alpha Inhibitors.
PLoS Med 2006 Nov; 3(11) :e511.

Edward Tobinick MD, Hyman Gross MD, Alan Weinberger MD, Hart Cohen MD FRCPC
TNF-alpha Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot Study.
MedGenMed 2006; 8(2) :25. [link to PubMed listing]

Edward Tobinick MD
The Cerebrospinal Venous System: Anatomy, Physiology, and Clinical Implications.
MedGenMed 2006; 8(1) :53.

The above articles have been cited by the following scientific publications:

Griffin, W.S., Perispinal etanercept: Potential as an Alzheimer therapeutic. J Neuroinflammation, 2008. 5(1): p. 3.] [link to full-text PDF].

Van Eldik, L.J., W.L. Thompson, H.R. Ranaivo, H.A. Behanna, and D.M. Watterson, Proinflammatory Cytokine Upregulation as a Therapeutic Target for Neurodegenerative Diseases: Function-Based and Target-Based Discovery Approaches. International Review of Neurobiology, 2007. 82: p. 278-297.

Tweedie, D., K. Sambamurti, and N.H. Greig, TNF-alpha Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Curr Alzheimer Res, 2007. 4(4): p. 375-8.

Munoz, L., H. Ralay Ranaivo, L.J. Van Eldik, D.M. Watterson, and e. al., A novel p38 MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation, 2007. 4: p. doi:10.1186/1742-2094-4-21.

Rosenberg, P., Cytokine Inhibition for Treatment of Alzheimer's Disease. Medscape General Medicine: Neurology, 2006. 8(2).

Ranaivo, H.R., J.M. Craft, W. Hu, L. Guo, L.K. Wing, L.J. Van Eldik, and D.M. Watterson, Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci, 2006. 26(2): p. 662-70.

Pearce, J.M., The craniospinal venous system. Eur Neurol, 2006. 56(2): p. 136-8.

Hu, W., H.R. Ranaivo, L.J.V. Eldik, D.M. Watterson, and et. al., Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorganic & Medicinal Chemistry Letters, 2006. 17(2): p. 414-418.

Tubbs, R.S., A. Hansasuta, M. Loukas, R.G. Louis, Jr., M.M. Shoja, E.G. Salter, and W.J. Oakes, The basilar venous plexus. Clin Anat, 2007. 20(7): p. 755-9.

Citations to Dr. Tobinick's published articles related to disc-related pain, including sciatica, intractable back pain, and cervical radiculopathy

The articles:

1. Tobinick, E.L. and S. Britschgi-Davoodifar, Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly, 2003. 133(11-12): p. 170-7.

2. Tobinick, E.L., Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin Ther, 2003. 25(4): p. 1211-8.

3. Tobinick, E. and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85.

The above articles have been cited by the following scientific publications:

Aoki, Y., et al., Neuropathology of Discogenic Low Back Pain: A Review. The Internet Journal of Spine Surgery, 2005. 2(1).

Aoki, Y., et al., Distribution and immunocytochemical characterization of dorsal root ganglion neurons innervating the lumbar intervertebral disc in rats: a review. Life Sci, 2004. 74(21): p. 2627-42.

Bhargava, A., et al., Injection Therapy for Lumbar Radiculopathy. Current Opinion in Orthopedics, 2005. 16: p. 152-157.

Bianco, E., et al. Linea guida: Appropriatezza della diagnosi e del trattamento chirurgico dell'ernia del disco lombare sintomatica. in Linea guida: Italy. 2005. Italy: PNLG.

Cohen, S.P., et al., Lumbar discography: a comprehensive review of outcome studies, diagnostic accuracy, and principles. Reg Anesth Pain Med, 2005. 30(2): p. 163-83.

Cole, P. and X. Rabasseda, The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease. Drugs Today (Barc), 2004. 40(4): p. 281-324.

Furst, D.E., et al., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis, 2006. 65 Suppl 3: p. iii2-iii15.

Hildebrandt, A., et al., European guidelines for the management of chronic non-specific low back pain (Spanish version) (de la version espanola). On behalf of the COST B13 Working Group on Guidelines for Chronic Low Back Pain, 2005.

Irving, G., V. Goli, and E. Dunteman, Novel pharmacologic options in the treatment of neuropathic pain. CNS Spectrum, CME Accredited roundtable monograph, 2004.

Karppinen, J., et al., Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine, 2003. 28(8): p. 750-3; discussion 753-4.

Korhonen, T., et al., Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine, 2004. 29(19): p. 2115-9.

Mulleman, D., et al., Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-alpha antagonists. Joint Bone Spine, 2006. 73(3): p. 270-7.

Myers, R.R., W.M. Campana, and V.I. Shubayev, The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today, 2006. 11(1-2): p. 8-20.

Pasternack, F.R., L.P. Fox, and D.E. Engler, Silicone granulomas treated with etanercept. Arch Dermatol, 2005. 141(1): p. 13-5.

Quintao, N.L., et al., Long-lasting neuropathic pain induced by brachial plexus injury in mice: Role triggered by the pro-inflammatory cytokine, tumour necrosis factor alpha. Neuropharmacology, 2006. 50(5): p. 614-20.

Scheinfeld, N., The medical uses and side effects of etanercept with a focus on cutaneous disease. J Drugs Dermatol, 2004. 3(6): p. 653-9.

Sommer, C. and M. Schafers, Mechanisms of neuropathic pain: the role of cytokines. Drug Discovery Today: Disease Mechanisms, 2004. 1(4): p. 441-448.

Vogel, C., S. Stallforth, and C. Sommer, Altered pain behavior and regeneration after nerve injury in TNF receptor deficient mice. J Peripher Nerv Syst, 2006. 11(4): p. 294-303.

Yaksh, L. and L. Sorkin, Mechanisms of Neuropathic Pain. Current Medicinal Chemistry-Central Nervous System Agents, 2005. 5(2): p. 129-140.

1. Anderson, G.M., M.T. Nakada, and M. DeWitte, Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol, 2004. 4(4): p. 314-20.

2. Wacnik, P.W., et al., Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience, 2005. 132(2): p. 479-91.

3. Yan, L., et al., Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer, 2006. 42(6): p. 793-802.

4. Scallon, B.J., et al., A review of antibody therapeutics and antibody-related technologies for oncology. J Immunother, 2006. 29(4): p. 351-64.

1. Lai, S.T., Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis, 2005. 24(9): p. 583-91.

2. Tang, J. and R. Chan, Severe acute respiratory syndrome(SARS) in intensive care units(ICUs): limiting the risk to healthcare workers. Current Anaesthesia & Critical Care, 2004. 15(3): p. 143-155.

3. Oliveri, C. and R. Polosa, Etanercept in chronic severe asthma. Thorax, 2006. 61(7): p. 640; author reply 640.